Pulse Biosciences, Inc. 8-K Filing
Ticker: PLSE · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Pulse Biosciences, Inc. (ticker: PLSE) to the SEC on Apr 7, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on Which Registered Common stock, $0.001 par value per share PLSE The Nasdaq).
How long is this filing?
Pulse Biosciences, Inc.'s 8-K filing is 2 pages with approximately 555 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2026-04-07 08:59:37
Key Financial Figures
- $0.001 — ange on Which Registered Common stock, $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20260406_8k.htm (8-K) — 25KB
- ex_942349.htm (EX-99.1) — 18KB
- 0001437749-26-011546.txt ( ) — 177KB
- plse-20260407.xsd (EX-101.SCH) — 3KB
- plse-20260407_def.xml (EX-101.DEF) — 11KB
- plse-20260407_lab.xml (EX-101.LAB) — 15KB
- plse-20260407_pre.xml (EX-101.PRE) — 11KB
- plse20260406_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On April 7, 2026, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the first enrollment of patients in its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company's nPulse Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (the "Study"). The first seven patients in the Study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, by Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. The Company plans to enroll approximately 215 participants in the Study, across multiple clinical sites, and expects the primary endpoints will be assessed at 6 and 12 months post-ablation to measure procedural success and safety outcomes. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated April 7, 2026 - Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: April 7, 2026 By: /s/ Paul A. LaViolette Paul A. LaViolette Chief Executive Officer (Principal Executive Officer)